TNGX Should I Buy
-
$
0.000
0.000(0.000%)
At close0.000(0.000%)Aft-market
ET
Loading...
TNGX is not a good buy right now. The longer-term trend looks constructive (bullish moving averages), but near-term momentum is weakening (MACD negative/expanding) and options positioning is decisively bearish (heavy put bias). With no fresh news catalyst this week and no proprietary buy signals today, the risk/reward for an impatient buyer is unfavorable at current levels (~11.84 post-market).
Trend/structure: Moving averages are bullish (SMA_5 > SMA_20 > SMA_200), signaling an overall uptrend. However, momentum is deteriorating: MACD histogram is -0.105 and negatively expanding, which often precedes short-term pullbacks or chop.
Price levels: Post-market ~11.84 sits below the pivot (12.156), which keeps the near-term bias slightly defensive until it reclaims that area. Key support is S1 at 11.216 (a logical downside magnet if weakness continues). Below that, S2 is 10.636. Upside resistance is R1 13.096 then R2 13.676.
Oscillators: RSI(6) ~49.6 is neutral—no oversold condition to justify an “impatient” dip-buy.
Near-term expectancy (pattern-based): Model suggests ~50% chance of a small dip next day (-0.18%), but a positive skew over 1 week (+4.13%) and 1 month (+11.61%). Given current momentum/positioning, the path may include a retest of support before that upside plays out.
can continue to underpin sentiment.
Options market is strongly bearish (very high put/call ratios on both OI and volume), often a headwind for near-term price action.
Momentum weakening: MACD negative and expanding suggests the near-term move may still be down/choppy rather than an immediate breakout.
No fresh news this week: Lack of near-term catalysts can leave the stock vulnerable to technical selling/mean reversion.
Mixed sell-side view: Wolfe initiated at Peer Perform and specifically flagged the pancreatic cancer signal as looking weak—this is a tangible fundamental pushback versus the more bullish notes.
Latest reported quarter: 2025/Q3. Revenue: $53.811M, up +363.61% YoY (strong top-line growth). Profitability: Net income fell to $15.884M (down -154.46% YoY) and EPS to $0.13 (down -148.15% YoY), indicating earnings power worsened versus the prior-year quarter despite the revenue jump. Gross margin: 100% (flat YoY), consistent with milestone/contract-like revenue dynamics often seen in biotech—revenue strength is positive, but the YoY decline in earnings metrics weakens the “clean” growth narrative.
Recent trend: Net positive. Targets were raised and Buy/Overweight ratings dominate in the recent tape (Piper Sandler raised PT to $14 and kept Overweight; Stifel initiated Buy with $15; B. Riley raised PT to $14 and kept Buy). The main counterweight is Wolfe’s Peer Perform with a cautionary view on the strength of pancreatic cancer signal.
Wall Street pros: Multiple bullish firms see differentiation and sizable long-term revenue potential tied to vopimetostat; recent target raises suggest improving confidence. Wall Street cons: At least one credible shop questions signal strength, implying meaningful clinical/competitive execution risk.
Influential trading: Hedge funds and insiders are reported neutral (no significant trends). Congress trading: no recent data available.
